Kinch Michael S
Washington University in St Louis, 4240 Duncan Street, Suite 110, St Louis, MO 63110, USA.
Drug Discov Today. 2015 Feb;20(2):170-4. doi: 10.1016/j.drudis.2014.10.013. Epub 2014 Nov 4.
For a fortunate subset of pharmaceutical companies, a regulatory approval is the culmination of massive investment in time, work and money. What happens next? Some companies proceed to build a pipeline and obtain additional approvals. Others do not. In this present report, post-approval fate is evaluated and it was found that most companies are ultimately acquired. A subset achieved a second approval six-to-eight years after the first approval, whereas a shrinking subset, designated as 'singlets', remains active in drug discovery with only a single approval. The likelihood that a company will remain a singlet or be acquired relates to therapeutic indication, with oncology associated with increased acquisition potential and infectious-disease-based companies being less commonly acquired.
对于一部分幸运的制药公司来说，监管批准是在时间、工作和资金上巨额投入的最终成果。接下来会发生什么呢？一些公司会着手建立产品线并获得更多批准。其他公司则不会。在本报告中，对批准后的命运进行了评估，结果发现大多数公司最终被收购。一部分公司在首次批准后的六到八年获得了第二次批准，而一小部分被称为“单药公司”的公司，在只有一项批准的情况下仍活跃于药物研发领域。一家公司保持单药状态或被收购的可能性与治疗适应症有关，肿瘤学领域的公司被收购的可能性增加，而基于传染病领域的公司被收购的情况则较少见。
